Address
Stonebridge House
Hatfield, CM22 7BD
United Kingdom of Great Britain and Northern Ireland (the)
Phone
442030084416
Website
Sector
Healthcare
Industry
Biotechnology
Employees
16
First IPO Date
January 07, 2002
| Name | Title | Pay | Year Born |
| Mark Eccleston | Chief Executive Officer, Director, Member of Scientific & Commercial Advisory Board | 83,381 | 1971 |
| James Gerry Desler | Chief Financial Officer, Company Secretary & Executive Director | 66,450 | 1945 |
| Andrew Carnegie | Head of Strategic Commercial Development | 0 | N/A |
| Mark Treharne | Corporate Development Manager | 0 | N/A |
| Kumar Nawani | Head of Operations | 0 | N/A |
ValiRx plc is a UK-based biopharmaceutical company dedicated to pioneering oncology therapeutics and companion diagnostics. Among its primary drug candidates is VAL201, a small molecule that has progressed through Phase I/II trials, aiming to treat prostate cancer and other hormone-dependent solid tumors, including breast and ovarian cancer. Another key candidate, VAL401, a reimagined version of the antipsychotic drug risperidone, has successfully completed Phase II clinical trials for addressing non-small cell lung cancer. The company's pipeline also features VAL301, a peptide currently in pre-clinical development for treating endometriosis in women. Additionally, BC201, a compound combining the peptide ingredient from VAL201/VAL301 with complementary active components, is being developed to alleviate severe symptoms of COVID-19. ValiRx plc was established in 2000 and is headquartered in Hatfield, United Kingdom.